Stock Ratings / Health Care / SRZN / dividends

VALN (58) ETRA (48) ENTX (40) RGNX (39) ⌘ Pro Terminal →

Surrozen Inc. (SRZN) Dividend Safety Gauge & 10-Year DRIP Compounder

$29.46 -2.93% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $29.25

Surrozen Inc. (SRZN) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $524.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $29.25 (-0.72%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-14% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SRZN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (27/100 Composite)

🔍 WHY SRZN SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (30% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▲ #2 Bullish Driver: Macro Regime Fit+6/20 pts (22% of score)

FRED Regime × Technicals: 68% of 52W Range • RSI-14 at 58 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$29.69-21.1% Next Q

Q2 (-2Q)

Grade E$23.44+8.7% Next Q

Q3 (-1Q)

Grade E$25.48+15.6% Next Q

Current

Grade E$29.46-10.3% Hist 90D α

Trajectory: E (35) → E (27)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SRZN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SRZN currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($24.31) and Max Pain ($30.93) forces dealer call-delta covering toward $39.72.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SRZN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SRZN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 27%NO 73%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SRZN)

✓Walkthrough of SRZN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SRZN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.80%📐 HORIZONTAL RANGE

2026-10-30O $29.32H $29.51L $27.72C $29.46VOL 231.9K

RES: $42.49SUP: $14.77SMA50: $24.31SMA200: $25.10

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SRZN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SRZN Butterfly Map → + Track SRZN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SRZN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SRZN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SRZN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SRZN)

Health Care Rank #975 of 1016 ⚔️ VALN vs SRZN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SRZN vs. VALN, ETRA, ENTX, RGNX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Surrozen Inc. (SRZN) ranks #975 by composite RQD confidence (27/100, grade E) and #438 by equity capitalization ($524.4M). Within this direct 5-issuer industry benchmark cohort, SRZN leads on earnings valuation at N/A trailing P/E, while ENTX leads on capital efficiency and profitability with -33.6% ROIC and 0.0% gross margin. VALN currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with SRZN at 27/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SRZN ACTIVE Surrozen Inc.	E	27/100	—	—	-35.0%	-2.93%	$524.4M	Benchmark Subject
VALN Valneva SE	D+	58/100	—	—	—	-0.52%	$541.8M	/valn-vs-srzn →
ETRA Electra Therapeutics Inc.	D	48/100	—	—	—	-3.79%	$542.3M	/etra-vs-srzn →
ENTX Entera Bio Ltd.	D-	40/100	—	0.0%	-33.6%	+0.65%	$542.6M	/entx-vs-srzn →
RGNX REGENXBIO Inc.	D-	39/100	—	—	-35.0%	+2.35%	$489.2M	/rgnx-vs-srzn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001824893

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Surrozen Inc. (SRZN) reported GAAP revenue of $3.5M (-67.4% vs. FY2024 revenue of $10.7M ) , GAAP net income of -$242.0M, operating cash flow of -$30.2M, and free cash flow of -$30.4M (-72.0% YoY). On the balance sheet, SRZN closed FY2025 with $98.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$3.5M	-$242.0M	-$30.2M	-$30.4M	$98.7M	—
FY2024 (FY)	2024-12-31	$10.7M	-$63.6M	-$17.6M	-$17.7M	$48.5M	—
FY2023 (FY)	2023-12-31	$0	-$43.0M	-$40.4M	-$40.4M	—	—

3. SRZN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SRZN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Surrozen Inc. (NASDAQ: SRZN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $29.46 (-2.93% 1D, market cap $524.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SRZN ranks #975 in composite RQD confidence.

How does SRZN compare to VALN and ETRA in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SRZN carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VALN (Valneva SE) holds a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $541.8M) and ETRA (Electra Therapeutics Inc.) posts a D grade (48/100 RQD, P/E N/A, ROIC —, cap $542.3M). Among the 5-stock peer group, SRZN leads on earnings multiple (N/A) while ENTX leads on capital efficiency (-33.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SRZN?

Per SRZN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001824893), Surrozen Inc. generated $3.5M in revenue (-67.4% YoY), -$242.0M in net income, and -$30.4M in free cash flow against $98.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SRZN trading relative to its 50-day, 200-day, and 52-week technical levels?

SRZN last traded at $29.46 (-2.93% on volume of 254,742 shares), positioning the stock +21.18% above its 50-day simple moving average ($24.31) and +17.37% above its 200-day simple moving average ($25.10). Across its 52-week range of $11.39 to $37.83, SRZN sits at the 68.3% percentile with a 14-day RSI of 58.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($25.78 to $33.14).

SRZN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does SRZN pay a dividend and is it safe?

Surrozen Inc. (SRZN) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: SRZN RQD Cockpit SRZN 12M Forecast SRZN Earnings & Move SRZN Dividends & DRIP SRZN Insiders & 13F SRZN Whale Options SRZN Profit Sankey SRZN News & Why